Clinical trials: Stage 0 Bladder Cancer
Recurrent Bladder Cancer, Stage 0 Bladder Cancer
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
This randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer.
- Conditions
- Recurrent Bladder Cancer, Stage 0 Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer
- Trial name
- NCT02252393
- Testing
- robot-assisted laparoscopic surgery, intraoperative complication management/prevention, quality-of-life assessment
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00003725
- Testing
- valrubicin, conventional surgery
- Where
- 53 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Anthra Pharmaceuticals
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding…
- Conditions
- Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
- Trial name
- NCT03552796
- Testing
- Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Sponsor
- University of Southern California
Bladder Cancer
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage…
- Trial name
- NCT00003129
- Testing
- valrubicin
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Bladder Cancer
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00014287
- Testing
- gemcitabine hydrochloride
- Sponsor
- University of Pittsburgh
Bladder Cancer
Eflornithine in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer.
- Trial name
- NCT00003814
- Testing
- eflornithine
- Where
- 61 sites in United States
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma, Infiltrative Bladder Carcinoma
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.
- Conditions
- Bladder Carcinoma, Infiltrative Bladder Carcinoma, Cystectomy
- Trial name
- LAPAINBLAD (NCT01245660)
- Testing
- LAPATINIB
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Bordeaux
Bladder Cancer
Quality of Life in Patients With Bladder Cancer
RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future.
- Trial name
- NCT00553215
- Testing
- quality-of-life assessment, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 2,700 people
- Sponsor
- University of Birmingham
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of selenium and vitamin E may stop cancer from growing or coming back.
- Trial name
- NCT00553345
- Testing
- selenium, vitamin E, chemoprevention
- Where
- United Kingdom
- Volunteers
- 515 people
- Sponsor
- University of Birmingham
Bladder Disease, Bladder, Neurogenic
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant.
- Conditions
- Bladder Disease, Bladder, Neurogenic, Bladder Cancer, Kidney Failure
- Trial name
- NCT06337942
- Testing
- Bladder Transplantation, Combined Kidney and Bladder Transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Los Angeles
Bladder Cancer
Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
- Trial name
- NCT00553566
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- University of Birmingham
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Bladder Cancer
Biological Therapy in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which type of BCG is more effective for bladder cancer.
- Trial name
- NCT00003779
- Testing
- Connaught, Tice
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Bladder Cancer
Suramin in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have recurrent bladder cancer.
- Trial name
- NCT00006476
- Testing
- suramin, conventional surgery
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cancer Research UK
Bladder Cancer
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00023842
- Testing
- BCG vaccine, mitomycin C, adjuvant therapy
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 97 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder…
- Trial name
- NCT00047216
- Testing
- tipifarnib
- Where
- 7 sites in United States, Canada
- Sponsor
- University Health Network, Toronto
Bladder Cancer
S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence…
- Trial name
- NCT00003824
- Testing
- cephalexin, surgical procedure, Ciprofloxacin
- Where
- 90 sites in United States
- Volunteers
- 114 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Neoplasms, Lung Neoplasms
Imaging Study for FdCyd and THU Cancer Treatment
Background: The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body.
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT01479348
- Testing
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)